Business
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer
About this update from Lantern Pharma Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that the Company will participate and present at four upcoming conferences:\n\n\n\nBiotech CEO Summit USA in La Jolla, CA from July 17-19, 2023. Panna Sharma, Lantern’s CEO and President will be participating.\nConference Website: https://www.biotechceosummit.com\n\n\n\n\n\nCancer Molecular Therapeutics Research Association Conference, in Watkins Glen, NY from July 23-27, 2023. Kishor Bhatia Ph.D., Lantern’s Chief Scientific Officer, will be participating, presentation details TBA.\nConference Website/Registration: https://www.cancermoleculartherapeutics.org\n\n\n\n\n\nSociety of Neuro-Oncology/American Society of Clinical Oncology CNS Cancer Conference in San Francisco, CA, on August 10th, 2023 from 5:30-7:30 p.m. PT.\nPresentation Title: LP-184, a novel acylfulvene-derived tumor site activated small molecule inhibits adult and pediatric CNS tumor cell growth\nConference Website/Registration:\nhttps://www.soc-neuro-onc.org/WEB/Event_Content/2023_SNO_ASCO_CNS_Cancer_Conference.aspx\n\n\n\n\n\nInternational Conference on Drug Conjugates for Directed Therapy in Darmstadt, Germany on Thursday, August 24th, 2023 from 9:45-10:15 a.m. CEST.\nPresentation Title: In-silico Approach for the Identification of ADC Targets with Improved Tumor Selectivity\nConference Website/Registration:\nhttps://www.uni-bielefeld.de/fakultaeten/chemie/projects/magicbulletreloaded/conference/index.xml\n\n\n\nFurther details on the data and findings presented at the scientific conferences will be announced following the conference presentations.\n\n\nAbout Lantern Pharma:\n\n\nLantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the develo...